Advances in antibody technologies

Recent deals involving bispecific antibodies illustrate the growing breadth of cancer immunotherapy applications for this platform.

Singh Biotechnology is developing novel camelid–derived single domain antibodies that target key intracellular molecular switches in cancer. The technology has therapeutic applications beyond cancer, and the company is seeking partners to advance its assets from preclinical to commercialization.

With a unique ownership structure and stable long-term funding, Biomed Valley Discoveries fuels a virtuous circle of investment, profit and research for the benefit of patients with unmet medical needs.

Ab Studio combines traditional approaches with computer-aided design to speed development of therapeutic antibodies.

Adrenomed AG is translating the concept of precision medicine to acute care with a biomarker-guided antibody therapy for sepsis and septic shock.

Alloy Therapeutics, a biotechnology ecosystem company, is committed to providing affordable and non-exclusive access to a portfolio of foundational tools and services for the drug discovery community. Alloy’s lead platform is ATX-Gx, the world’s first royalty-free humanized mouse discovery platform.

With its innovative antibody discovery platform ADLib, Chiome Bioscience is nurturing a pipeline of antibody candidates ready for partnering.

ImmunoPrecise offers a comprehensive suite of solutions to rapidly deliver high-performing therapeutic antibodies.

Unparalleled success in antibody discovery and development.